Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bimatoprost
Therapeutic Area : Ophthalmology
Study Phase : Approved
Sponsor : Famar
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Under the agreement, Medicom has acquired the ownership of the pharmaceutical dossier of Zimed (bimatoprost), a preservative free eye drop solution, which is already registered in the UK and 5 EU countries with plans to commercialise the asset globally.
Brand Name : Zimed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 09, 2021
Lead Product(s) : Bimatoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Approved
Sponsor : Famar
Deal Size : Undisclosed
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?